Uterine glandular area during the menstrual cycle and the effects of different in-vitro fertilization related hormonal treatments

• Published in: Human reproduction (Oxford) 1996-02, Vol.11 (2), p.376-379
• Main Authors: Rogers, P.A.W, Hosie, M.J., Ortis, A., Susil, B., Leeton, J., Murphy, C.R.
• Format: Article
• Language: English
• Subjects: Biopsy; Clomiphene - therapeutic use; endometrium; Epithelium - drug effects; Epithelium - pathology; Estrogen Replacement Therapy; Female; Fertilization in Vitro; gland; Hormones - therapeutic use; Humans; Infertility, Female - pathology; Infertility, Female - physiopathology; Infertility, Female - therapy; IVF; Menotropins - therapeutic use; Menstrual Cycle; superovulation; Uterus - drug effects; Uterus - pathology
• ISSN: 0268-1161; 1460-2350
• DOI: 10.1093/HUMREP/11.2.376

The human uterine glandular epithelium undergoes a sequence of well characterized changes during the menstrual cycle that presumably play an important role in preparation for blastocyst implantation. The aim of this study was to measure objectively glandular volume over the entire menstrual cycle and compare the results with eight different clinical superovulation or hormone replacement therapy (HRT) subject groups. Endometrial biopsies were taken from control normal menstrual cycle subjects (n = 96), and eight other smaller groups of women who had received different in-vitro fertilization (TVF) related treatments. The total area of glandular epithelium was objectively measured from routine histological slides using computerized image analysis. Control menstrual cycle results showed a significantly greater gland area in the early secretory stage of the cycle than at any time between the early proliferative through to the mid-late proliferative stages (P < 0.05). FVF patients receiving clomiphene citrate and human menopausal gonadotrophin had a significantly smaller glandular area than those in the control groups at equivalent stages of the menstrual cycle. The use of progesterone supplementation removed this significant difference. Patients on the ‘Flare“ regime had the highest gland area, although this was not significantly different from controls. Buserelin down-regulation gave a gland area that was closest to the normal cycle controls. The three HRT groups showed high variability in gland volume between patients. The results from this study demonstrate that superovulation can cause significant alterations in endometrial gland volume, but that these do not necessarily preclude implantation.